Sorrento Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Warrants
02 juil. 2019 12h40 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
Sorrento Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
28 juin 2019 08h37 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 28, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn...
Sorrento Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for “Off-The-Shelf” Cell Therapy
19 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
“CD38 Therapeutics” Business Unit formed to focus on development of CD38-directed immunotherapies for potential out-licensing, collaboration and/or other strategic considerations○ Clinical...
Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)
14 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 14, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announces today that senior management will be presenting in the upcoming JMP Life Sciences...
Sorrento to Explore Potential Initial Public Offering of Scilex Holding Company
12 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 12, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) today announced that it is exploring the possibility of an initial public offering of its...
Sorrento Announces Cannabidiol (CBD) Global Joint Ventures and Commercial Strategic Partnerships
04 juin 2019 07h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, June 04, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Sorrento, Nasdaq: SRNE) announces that it has formed a Chinese joint venture, Shenzhen Yunma Biotechnology Co., Ltd....
Sorrento Therapeutics to Present at 20th Annual B. Riley FBR Investor Conference in Los Angeles (ca).
21 mai 2019 18h25 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, May 21, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in the upcoming FB...
Sorrento Establishes Business Unit to Address Market Opportunity for Proprietary Water Soluble Cannabidiol (CBD) Formulations
16 avr. 2019 09h00 HE
|
Sorrento Therapeutics, Inc.
Cannabidiol (CBD) material from virtually THC-free (<0.3%) hemp plants sourcesExcipients on the FDA approved GRAS (Generally Regarded As Safe) listWater soluble formulations with target...
Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration
10 avr. 2019 09h00 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study...
CORRECTING and REPLACING - Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001
11 mars 2019 12h54 HE
|
Sorrento Therapeutics, Inc.
SEOUL, South Korea and SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sorrento Therapeutics, Inc. (Nasdaq: SRNE), please note that in the...